Jun 2026 (Q2 FY26) — Aug 6, 2026
Nuvation Bio Q2 FY26 — Strong IBTROZI First-Line Growth and Expanded Safusidenib Program
Read the full callNuvation Bio (NUVB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Nuvation Bio earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 31.7 | +555.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -161.1 | +1154.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -62.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.48 +0.67% · +$0.03
Performance +31.4% 1Y
1Y: $3.41 on 17 Oct 2025 → $4.48. High $9.54 (22 Dec 2025), low $3.41 (17 Oct 2025).
- Previous close
- $4.45
- 52-week range
- $3.7 – $9.54
- One year
- +21.08%
Overview
- Symbol
- NUVB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Nuvation Bio earnings calls (NUVB)
Financials
What the filings say
Net profit, year on year: −6% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 6 | 3 | 5 | 13 | 42 | 83 | 32 |
| Operating profit | -48 | -54 | -59 | -64 | -56 | -34 | 4 | -51 |
| Operating margin | −6616.4% | −944.5% | −1913.2% | −1315.7% | −430.1% | −81.3% | 4.7% | −161.1% |
| Other income | 7 | 4 | 6 | 5 | 1 | -3 | 2 | -12 |
| Interest | 0 | 0 | 0 | 0 | 7 | 7 | 7 | 7 |
| Profit before tax | -41 | -49 | -53 | -59 | -56 | -37 | 5 | -63 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -41 | -49 | -53 | -59 | -56 | -37 | 5 | -63 |
| EPS ($ per share) | -0.15 | — | -0.16 | -0.17 | -0.16 | — | 0.02 | -0.18 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 289 | 910 | 928 | 948 | 1,374 | 1,421 |
| Reserves | -76 | -163 | -267 | -343 | -911 | -1,115 |
| Total liabilities | 7 | 30 | 17 | 16 | 77 | 289 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 | 1 |
| Investments | 186 | 633 | 560 | 569 | 467 | 365 |
| Total assets | 222 | 776 | 672 | 621 | 541 | 595 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -37 | -68 | -96 | -68 | -130 | -173 |
| Cash from investing | -70 | -455 | 63 | 9 | 123 | 100 |
| Cash from financing | 133 | 626 | 1 | 1 | 0 | 203 |
| Net cash flow | 26 | 103 | -31 | -58 | -7 | 128 |
| Capital expenditure | — | — | — | — | 0 | -8 |
| Free cash flow | — | — | — | — | -130 | -181 |
Insider filings
40 filings between Oct 27, 2025 and Aug 19, 2026.
Open market
decisions to buy or sellPurchases
$118.3K
1 purchase by 1 insider
Sales
$9.68M
17 sales by 6 insiders
47% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 1
- Award — granted as compensation
- 21
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hattersley Gary | — | $3.88M | Aug 19, 2026 |
| Liu Dongfang | — | $1.87M | Apr 17, 2026 |
| Wentworth Kerry | — | $1.47M | Jun 23, 2026 |
| Hanley David C. | — | $1.43M | Nov 19, 2025 |
| Markel Stacy | — | $753.2K | Jun 23, 2026 |
| Sauvage Philippe | — | $286.4K | Jun 23, 2026 |
| Mashal Robert | $118.3K | — | Jun 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 19, 2026 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 100,000 | $709.2K |
| Aug 19, 2026 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 plan | 100,000 | $187.0K |
| Jul 15, 2026 | Sauvage Philippe Chief Financial Officer | Option exercise | 1 | $2 |
| Jul 15, 2026 | Sauvage Philippe Chief Financial Officer | Option exercise | 39,999 | $86.8K |
| Jun 23, 2026 | Markel Stacy CHIEF PEOPLE OFFICER | Sale 10b5-1 plan | 125,000 | $753.2K |
| Jun 23, 2026 | Sauvage Philippe Chief Financial Officer | Option exercise 10b5-1 plan | 47,668 | $103.4K |
| Jun 23, 2026 | Sauvage Philippe Chief Financial Officer | Sale 10b5-1 plan | 47,668 | $286.4K |
| Jun 23, 2026 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise 10b5-1 plan | 90,380 | $169.0K |
| Jun 23, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 plan | 63,000 | $184.6K |
| Jun 23, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 plan | 63,000 | $379.2K |
| Jun 23, 2026 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise 10b5-1 plan | 34,620 | $60.2K |
| Jun 9, 2026 | Mashal Robert Director | Purchase | 25,000 | $118.3K |
| Apr 17, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 plan | 36,750 | $184.3K |
| Apr 17, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 plan | 36,750 | $107.7K |
| Apr 17, 2026 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise 10b5-1 plan | 50,000 | $97.0K |
| Apr 17, 2026 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 50,000 | $251.0K |
| Apr 6, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 plan | 100,000 | $194.0K |
| Apr 6, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 plan | 100,000 | $187.0K |
| Apr 6, 2026 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 plan | 200,000 | $903.6K |
| Feb 27, 2026 | Makunje Moses SEE REMARKS | Award | 50,761 | $0 |
| Dec 1, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 150,000 | $1.17M |
| Dec 1, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 150,000 | $439.5K |
| Nov 26, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 10,000 | $36.1K |
| Nov 26, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 10,000 | $80.0K |
| Nov 25, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 10,000 | $36.1K |
| Nov 25, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 10,000 | $75.0K |
| Nov 20, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 20,000 | $37.4K |
| Nov 20, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise | 69,051 | $120.1K |
| Nov 20, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Sale | 69,051 | $499.0K |
| Nov 20, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise | 300,000 | $582.0K |
| Nov 20, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Sale | 300,000 | $2.17M |
| Nov 20, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 20,000 | $140.1K |
| Nov 19, 2025 | Hanley David C. CHIEF TECHNICAL OPERATIONS | Option exercise | 200,000 | $374.0K |
| Nov 19, 2025 | Hanley David C. CHIEF TECHNICAL OPERATIONS | Sale | 200,000 | $1.43M |
| Nov 19, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 15,000 | $28.1K |
| Nov 19, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 15,000 | $76.6K |
| Nov 17, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise | 15,000 | $28.1K |
| Nov 17, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale | 15,000 | $71.5K |
| Oct 27, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 100,000 | $502.5K |
| Oct 27, 2025 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 plan | 100,000 | $174.0K |
| Jun 18, 2025 | Markel Stacy CHIEF PEOPLE OFFICER | Purchase | 10,000 | $17.1K |
| Jun 17, 2025 | Sauvage Philippe Chief Financial Officer | Purchase | 4,000 | $7.2K |
| Jun 16, 2025 | Wentworth Kerry CHIEF REGULATORY OFFICER | Purchase | 26,000 | $46.5K |
| Jun 16, 2025 | Wentworth Kerry CHIEF REGULATORY OFFICER | Purchase | 24,000 | $43.2K |
| Jun 16, 2025 | Sjogren Colleen Chief Commercial Officer | Purchase | 50,000 | $90.3K |
| Jun 16, 2025 | Sauvage Philippe Chief Financial Officer | Purchase | 3,300 | $6.1K |
| Jun 16, 2025 | Hung David PRESIDENT AND CEO | Purchase | 500,000 | $893.5K |
| May 2, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise 10b5-1 plan | 20,000 | $38.8K |
| May 2, 2025 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 20,000 | $50.0K |
| Apr 7, 2025 | Hung David PRESIDENT AND CEO | Purchase | 300,000 | $487.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Nuvation Bio Inc.
Free account. Everything above stays public.
Write why you follow Nuvation Bio Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading